Key Highlights

  • Silex Systems reported FY26 Revenue from continuing operations of AUD 21.6 million, while its net loss narrowed to AUD 38.6 million.
  • In September 2026, Global Laser Enrichment signed an exclusive agreement with Cameco covering future uranium products from the proposed Paducah facility.
  • The US Nuclear Regulatory Commission issued its final environmental impact statement in October 2026, advancing the project's regulatory assessment.
  • Silex held approximately AUD 180.7 million in cash and term deposits at 30 June 2026, with no corporate debt, while progressing uranium and quantum silicon commercialisation programmes.

Silex Systems Limited (ASX:SLX) is an Australian technology company developing laser-based isotope separation technology for uranium enrichment and other specialised applications. Its principal commercialisation programme involves Global Laser Enrichment (GLE), a US-based joint venture developing the proposed Paducah Laser Enrichment Facility in Kentucky. Silex also operates a quantum silicon initiative targeting the production of enriched silicon-28 for advanced computing applications. During 2026, the company progressed commercial agreements, regulatory assessments and technology development, although its proposed uranium enrichment facility remains subject to licensing, financing and further technical milestones.

Cameco Offtake Agreement and Uranium Commercialisation

In September 2026, Global Laser Enrichment announced an exclusive offtake agreement with Cameco covering future production from the proposed Paducah Laser Enrichment Facility.

Under the arrangement, Cameco is expected to purchase the plant's future natural-grade uranium hexafluoride and enriched uranium products.

The agreement provides a proposed commercial sales channel for uranium products that could be manufactured using Silex's laser enrichment technology.

The pricing mechanism is linked to Cameco's realised prices from its long-term uranium contracting portfolio, after relevant selling costs.

Silex owns 51% of GLE, while Cameco holds the remaining 49%.

Cameco also retains an option to acquire an additional 26% interest in the venture, subject to the terms of the existing agreement.

Although the offtake arrangement supports commercial planning, future revenue remains dependent on the successful construction, commissioning and operation of the Paducah facility.

Paducah Environmental Review and Licensing Progress

The proposed Paducah Laser Enrichment Facility is being developed at a former uranium enrichment site in Kentucky, United States.

The project is designed to process depleted uranium hexafluoride material using Silex's laser isotope separation technology.

This process aims to recover commercially usable uranium products and support domestic nuclear fuel supply.

In October 2026, the US Nuclear Regulatory Commission issued its final environmental impact statement for the proposed facility.

The development represents an important milestone in the project's regulatory review.

However, the environmental assessment does not constitute final approval to construct or operate the plant.

The regulator must also complete its safety evaluation and associated licensing procedures.

GLE is targeting receipt of the necessary operating licence as early as calendar 2027.

The proposed facility is intended to support production of natural-grade uranium hexafluoride and potentially additional enriched uranium products.

Commercial operations are targeted for approximately 2030, subject to regulatory approval, technology readiness, financing and a final Investment decision.

FY26 Financial Performance and Funding Position

For the financial year ended 30 June 2026, Silex reported revenue from continuing operations of approximately AUD 21.6 million, compared with AUD 12.2 million in FY25.

Revenue included AUD 7.6 million associated with a technology commercialisation milestone payment.

The milestone followed independent validation of the SILEX uranium enrichment technology at Technology Readiness Level 6 during October 2025.

Silex received the related USD 5 million payment in December 2025.

The company recorded an FY26 net loss of approximately AUD 38.6 million, compared with AUD 42.6 million in the previous financial year.

At 30 June 2026, Silex held approximately AUD 180.7 million in cash and term deposits and reported no corporate debt.

The balance provides funding capacity for ongoing technology development and operating activities.

However, the commercial-scale Paducah project will require substantial additional Capital before production can begin.

Technology Development and Government Support

Silex continues developing its uranium enrichment technology towards commercial-scale deployment.

The SILEX process uses laser-based isotope separation rather than conventional centrifuge technology.

Its commercial potential depends on demonstrating reliable operation, competitive processing costs and performance at the scale required for industrial production.

The technology reached Technology Readiness Level 6 in October 2025, while further work towards Level 7 remains important.

In January 2026, GLE was selected for a US Department of Energy award of up to USD 28 million for technology development, subject to final arrangements.

The proposed Paducah project has also received preliminary approval for incentives of up to approximately USD 98.9 million from Kentucky and local authorities.

These incentives depend on qualifying investment, employment and other conditions.

Quantum Silicon and Development Risks

Alongside uranium enrichment, Silex is developing a Quantum Silicon production facility in Sydney.

The project aims to manufacture enriched silicon-28, a specialised material being investigated for silicon-based quantum computing.

Construction of the production facility was completed in June 2026, with commercial production targeted for calendar 2027.

However, customer Demand and the scale of future commercial opportunities remain uncertain.

For the uranium business, the principal risks include regulatory delays, technology scale-up, financing requirements and construction expenditure.

The final investment decision for Paducah has not yet been made, and commercial production will depend on completing feasibility assessments and securing the necessary capital.

Key Insights

Silex Systems Limited (ASX:SLX) advanced its uranium enrichment commercialisation programme during 2026 through a Cameco offtake agreement and progress in the Paducah regulatory review. Its FY26 financial position provides resources for continued technology development, while the proposed commercial facility remains dependent on further technical, licensing and funding milestones. The company is also progressing its Quantum Silicon project as a separate potential revenue opportunity. Successful technology demonstration and project financing will remain central to its longer-term outlook.